Comparative Pharmacology
Head-to-head clinical analysis: INREBIC versus TOFACITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INREBIC versus TOFACITINIB.
INREBIC vs TOFACITINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fedratinib is a selective Janus kinase 2 (JAK2) inhibitor. It inhibits JAK2 and its mutant forms, including JAK2V617F, leading to reduced phosphorylation of signal transducer and activator of transcription (STAT) proteins and decreased proliferation of abnormal hematopoietic cells.
Janus kinase (JAK) inhibitor, primarily inhibiting JAK1 and JAK3, thereby modulating the JAK-STAT signaling pathway to reduce cytokine production and immune cell activation.
100 mg orally twice daily continuously until disease progression or unacceptable toxicity.
5 mg orally twice daily; extended-release formulation 11 mg orally once daily. For rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. For ulcerative colitis, induction: 10 mg orally twice daily for 8 weeks, then maintenance 5 mg twice daily.
None Documented
None Documented
Clinical Note
moderateTofacitinib + Digoxin
"Tofacitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTofacitinib + Bendroflumethiazide
"Tofacitinib may increase the bradycardic activities of Bendroflumethiazide."
Clinical Note
moderateTofacitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tofacitinib."
Clinical Note
moderateTofacitinib + Erythromycin
Terminal elimination half-life approximately 14 hours; supports twice-daily dosing for steady-state attainment within 3 days
Terminal half-life approximately 3.3 hours in healthy volunteers. In patients with rheumatoid arthritis, effective half-life ~3-6 hours due to reversible binding to JAK enzymes. No significant accumulation at steady state.
Fecal (77.6% as metabolites, 2.2% as unchanged drug); renal (8.5% as metabolites, <1% as unchanged drug)
Primarily renal (70%) with 30% excreted unchanged in urine. Fecal elimination accounts for 20% (<1% unchanged). Minor biliary excretion.
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor
"The metabolism of Erythromycin can be decreased when combined with Tofacitinib."